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The novel respiratory disease COVID-19 produces varying symp-
toms, with fever, cough, and shortness of breath being common. 
In older adults, we found that preexisting dementia is a major risk 
factor (odds ratio [OR] = 3.07, 95% CI: 1.71 to 5.50) for COVID-19 
severity in the UK Biobank (UKB) (1). In another UK study of 16,749 
patients hospitalized for COVID-19 (2), dementia was among the 
common comorbidities and was associated with higher mortality. 
Additionally, impaired consciousness, including delirium, is common 
in severe cases (3). The ApoE e4 genotype is associated with both 
dementia and delirium (4), with the e4e4 (homozygous) genotype 
associated with a 14-fold increase in risk of Alzheimer’s disease 
(5) compared to the common e3e3 genotype, in populations with 
European ancestries. We, therefore, aimed to test associations be-
tween ApoE e4 alleles and COVID-19 severity, using the UKB data.
UKB is a community cohort currently aged 48 to 86 (6). COVID-
19 laboratory test results for UKB participants in England are 
available from March 16 to April 26, 2020, the peak period of 
COVID-19 incidence in the current outbreak. During this period, 
COVID-19 testing was largely restricted to hospital inpatients with 
clinical signs of infection, and therefore test positivity is a marker of 
severe COVID-19 infection (7).
We analyzed UKB data from genetically European ancestry 
participants (8) (n  =  451,367, 90% of sample) attending baseline 
assessment centers in England (n  =  398,073), excluding partici-
pants who died before the epidemic (n = 15,885). Single nucleotide 
polymorphism (SNP) data for rs429358 and rs7412 was used to 
determine ApoE genotypes: ApoE e4e4 homozygotes (n  =  9,022, 
3%), e3e4 (n = 90,469, 28%), and e3e3 (most common genotype, 
n = 223,457, 69%) genotype groups (final n = 322,948). Mean age 
was 68  years (SD  =  8) with 176,951 females (55%). There were 
622 positive COVID-19 patients (Table 1) including 37 with e4e4 
(positivity rate: 410/100,000) and 401 with e3e3 (179 per 100,000). 
A logistic regression model was used to compare e3e4 or e4e4 geno-
types to e3e3 for COVID-19 positivity status, adjusted for: sex; age 
at the COVID-19 test or age on April 26, 2020 (the last test date); 
baseline UKB assessment center in England; genotyping array type; 
and the top five genetic principal components (accounting for pos-
sible population admixture).
ApoE e4e4 homozygotes were more likely to be COVID-19 
test positives (OR = 2.31, 95% CI: 1.65 to 3.24, p = 1.19 × 10–6) 
compared to e3e3 homozygotes (Table  1). The association was 
similar after removing participants with ApoE e4 associated dis-
eases that were also linked to COVID-19 severity: participants 
without dementia (OR = 2.39, 95% CI: 1.71 to 3.35); hypertension 
(OR = 2.41, 95% CI: 1.56 to 3.74); coronary artery disease (myo-
cardial infarction or angina) (OR = 2.43, 95% CI: 1.69 to 3.50) or 
type 2 diabetes (OR = 2.51, 95% CI: 1.77 to 3.55) (Table 1), based 
on preexisting diagnoses from baseline self-reports or hospital dis-
charge statistics (updated to March 2017). The estimates were little 
changed using 136,146 participants with additional general practice 
data (up to 2017): participants without dementia (OR = 2.53, 95% 
CI: 1.46 to 4.39); hypertension (OR = 2.67, 95% CI: 1.34 to 5.32); 
coronary artery disease (OR = 2.86, 95% CI: 1.65 to 4.98) or type 
2 diabetes (OR = 2.73, 95% CI: 1.57 to 4.76). The results were also 
similar after excluding 51,430 participants related to the third de-
gree or closer (OR = 2.34, 95% CI: 1.62 to 3.38). Of 622 included 
participants who tested positive for COVID-19, 417 (67%) were 
noted to the laboratory to be inpatients when the sample was taken: 
unfortunately, data on later admission to hospital is not available 
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made little difference to the excess risk associated with ApoE e4e4 
status (OR = 2.32, 95% CI: 1.54 to 3.29), compared to OR = 2.31 
(95% CI: 1.65 to 3.24) using all the tested samples.
In conclusion, the ApoE e4e4 allele increases risks of severe 
COVID-19 infection, independent of preexisting dementia, cardio-
vascular disease, and type-2 diabetes. ApoE e4 not only affects lipo-
protein function (and subsequent cardio-metabolic diseases) but also 
moderates macrophage pro-/anti-inflammatory phenotypes (9). The 
novel coronavirus SARS-CoV-2 causing COVID-19 uses the ACE2 
receptor for cell entry. ACE2 is highly expressed in type II alveolar 
cells in the lungs, where ApoE is one of the highly co-expressed genes 
(10). Further investigation is needed to understand the biological 
mechanisms linking ApoE genotypes to COVID-19 severity.
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Table 1. Risk of Severe COVID-19, Comparing Participants With ApoE e3e4 or e4e4 to e3e3 Genotypes in UK Biobank
n
Negative or  
not Tested Positive
Positivity Rate  
per 100,000 OR (95% CI)a p-value
All       
 e3e3 223,457 223,056 401 179 - -
 e3e4 90,469 90,285 184 203 1.14 (0.95, 1.35) .15
 e4e4 9,022 8,985 37 410 2.31 (1.65, 3.24) 1.19E-06
Excluding dementia     
 e3e3 222,968 222,574 394 177 - -
 e3e4 90,013 89,840 173 192 1.09 (0.91, 1.31) .338
 e4e4 8,877 8,840 37 417 2.39 (1.71, 3.35) 4.26E-07
Excluding hypertension     
 e3e3 151,018 150,792 226 150 - -
 e3e4 61,249 61,157 92 150 1.00 (0.79, 1.28) .981
 e4e4 6,120 6,098 22 359 2.41 (1.56, 3.74) 8.21E-05
Excluding coronary artery disease
 e3e3 204,017 203,684 333 163 - -
 e3e4 82,099 81,948 151 184 1.13 (0.93, 1.37) 0.207
 e4e4 8,164 8,132 32 392 2.43 (1.69, 3.50) 1.65E-06
Excluding type 2 diabetes     
 e3e3 211,482 211,136 346 164 - -
 e3e4 85,983 85,827 156 181 1.11 (0.92, 1.34) .275
 e4e4 8,616 8,581 35 406 2.51 (1.77, 3.55) 2.42E-07
Note: aAdjusted for sex, age at the COVID-19 test or age on April 26, 2020 (the last test date), assessment center in England, genotyping array type, and the 
top five genetic principal components.
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